Clinical Trials Logo

Clinical Trial Summary

Patients with advanced penile cancer have a poor prognosis (21% 2-year overall survival from moment of diagnosis) and high morbidity due to progressive locoregional disease. Translational studies show high rates of infiltrating immune cells and PD-L1 positivity, suggesting that immunotherapy may be beneficial in this disease. Atezolizumab, targeting PD-L1, is active in several cancer types and is generally well-tolerated. This study will investigate whether atezolizumab can be combined with radiotherapy to control locoregional lymph node disease. Furthermore, the activity of atezolizumab in advanced penile cancer patients will be investigated.


Clinical Trial Description

Rationale Patients with advanced penile cancer have a poor prognosis (21% 2-year overall survival from moment of diagnosis) and high morbidity due to progressive locoregional disease. Translational studies show high rates of infiltrating immune cells and PD-L1 positivity, suggesting that immunotherapy may be beneficial in this disease. Atezolizumab, targeting PD-L1, is active in several cancer types and is generally well-tolerated. This study will investigate whether atezolizumab can be combined with radiotherapy to control locoregional lymph node disease. Furthermore, the activity of atezolizumab in advanced penile cancer patients will be investigated. Objectives: 1. Efficacy of atezolizumab in advanced penile cancer patients. 2. Feasibility of a protracted schedule of radiotherapy on locoregional disease in combination with immunotherapy for advanced penile cancer Study design: Single-center, nonrandomized, Phase 2 study with 2 treatment arms. Study population: Men, ≥18 years of age, with advanced inoperable penile cancer, N=32. Intervention: All patients will receive atezolizumab, 1200 mg, every 3 weeks, by IV infusion. Patients in group A will additionally receive 33 fractions of 1.5 (locoregional affected lymph nodes) and 1.8 Gy (tumor+margin) irradiation, concurrently with atezolizumab treatment. Primary endpoint: Progression-free survival at 1 year. Main secondary endpoint: 2-year overall survival rate of the complete study population. Percentage of patients who complete the full course of radiotherapy in the radiotherapy/atezolizumab arm. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Patients will be treated every 3 weeks with atezolizumab for one year or until loss of clinical benefit. Atezolizumab is generally well tolerated although immune-related toxicity does occur. Toxicity of combining atezolizumab with a long course of radiotherapy is unknown and may result in increased toxicity. It is unknown whether atezolizumab will induce responses in patients with advanced penile cancer. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03686332
Study type Interventional
Source The Netherlands Cancer Institute
Contact
Status Completed
Phase Phase 2
Start date September 25, 2018
Completion date September 15, 2023

See also
  Status Clinical Trial Phase
Completed NCT05518201 - Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old Phase 1
Recruiting NCT04708470 - A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers Phase 1/Phase 2
Active, not recruiting NCT04357873 - Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations Phase 2
Terminated NCT00058448 - S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED) Phase 2
Recruiting NCT02817958 - Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis Phase 2
Completed NCT02280811 - T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers Phase 2
Recruiting NCT02994758 - Development of Diagnostics and Treatment of Urological Cancers N/A
Completed NCT00019110 - Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer Phase 1
Completed NCT04574427 - INtra-operative Evaluation of a Novel FLUorescENt C-mEt Tracer in Penile and Tongue
Recruiting NCT02012699 - Integrated Cancer Repository for Cancer Research
Recruiting NCT05946993 - Linking In With Advice and Supports for Men Impacted by Metastatic Cancer N/A
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting NCT05686226 - E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers Phase 2
Completed NCT05376202 - Image Guided Penile Cancer Surgery Phase 1
Recruiting NCT05264337 - Lymphedema After Urologic Surgery
Recruiting NCT03774901 - Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma Phase 2
Completed NCT01209325 - Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males Phase 2
Recruiting NCT05592639 - VideoEndoscopic Radical Inguinal Lymphadenectomy for Penile Cancer N/A
Completed NCT00066391 - Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer Phase 2
Not yet recruiting NCT06353906 - Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer Phase 2